Invictus RG Boosts Stake in DexCom, Inc. (DXCM)
Invictus RG boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 21.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,779 shares of the medical device company’s stock after purchasing an additional 674 shares during the period. Invictus RG’s holdings in DexCom were worth $541,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Renaissance Technologies LLC lifted its holdings in DexCom by 49.1% in the third quarter. Renaissance Technologies LLC now owns 583,059 shares of the medical device company’s stock worth $83,401,000 after purchasing an additional 191,916 shares during the period. GAM Holding AG raised its stake in DexCom by 29.7% during the third quarter. GAM Holding AG now owns 6,257 shares of the medical device company’s stock worth $895,000 after acquiring an additional 1,434 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in DexCom by 152.3% during the third quarter. Tower Research Capital LLC TRC now owns 3,759 shares of the medical device company’s stock worth $538,000 after acquiring an additional 2,269 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of DexCom in the third quarter valued at $12,925,000. Finally, Hsbc Holdings PLC boosted its holdings in DexCom by 52.6% in the third quarter. Hsbc Holdings PLC now owns 32,202 shares of the medical device company’s stock valued at $4,606,000 after acquiring an additional 11,100 shares during the last quarter. 99.05% of the stock is owned by institutional investors.
Shares of DXCM stock opened at $127.91 on Thursday. The company has a debt-to-equity ratio of 0.60, a current ratio of 4.71 and a quick ratio of 4.43. DexCom, Inc. has a 12-month low of $51.04 and a 12-month high of $152.14. The stock has a market cap of $11.36 billion, a price-to-earnings ratio of -220.53 and a beta of 0.55.
Several research analysts have weighed in on the company. Northland Securities raised DexCom from an “under perform” rating to a “market perform” rating in a research report on Wednesday, September 12th. Goldman Sachs Group upgraded DexCom from a “sell” rating to a “neutral” rating and set a $125.00 target price on the stock in a research report on Friday, October 19th. Stephens increased their price target on DexCom from $135.00 to $160.00 and gave the company an “overweight” rating in a research report on Thursday, August 23rd. Canaccord Genuity raised their target price on DexCom from $125.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, August 23rd. Finally, BidaskClub raised DexCom from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 21st. Nine research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. DexCom presently has a consensus rating of “Buy” and an average target price of $132.65.
In other news, VP Patrick Michael Murphy sold 2,372 shares of DexCom stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $143.69, for a total value of $340,832.68. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Kevin R. Sayer sold 25,495 shares of DexCom stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $143.62, for a total value of $3,661,591.90. The disclosure for this sale can be found here. In the last quarter, insiders sold 149,745 shares of company stock worth $21,210,998. Company insiders own 1.80% of the company’s stock.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Recommended Story: Call Option
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.